Person · CIK 1823563

Rebecca Chambers

Chief Financial Officer at Veracyte; director at Alamar Biosciences and Inari Medical

Earlier: Outset Medical

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$6.3M
Noticed on Form 144$2.8M
Bought on Form 4$0
Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Veracyte VCYTCommon StockDirectly166,025Sep 4, 2026 · Filing · EDGAR
Veracyte VCYTStock Option (right to buy)
exercise $23.73, expires Mar 6, 2033, into Common Stock
Directly42,956Mar 6, 2023 · Filing · EDGAR
Alamar Biosciences ALMRStock Option (Right to Buy)
exercise $7.60, expires Jan 14, 2036, into Common Stock
Directly140,612Apr 20, 2026 · Filing · EDGAR
Outset MedicalCommon StockDirectly13,597Jun 24, 2021 · Filing · EDGAR
Outset MedicalNon-Qualified Stock Option (right to buy)
exercise $6.25, expires Sep 10, 2029, into Common Stock
Directly77,745Jun 24, 2021 · Filing · EDGAR

Sold and noticed by quarter

Rebecca Chambers: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$2.5M$0Q1 2021: notice not machine-readableQ1 2021: $835K sold on Form 4Q2 2021: notice not machine-readableQ2 2021: $2.5M sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $56K noticed on Form 144Q2 2024: $56K sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $926K noticed on Form 144Q4 2024: $888K sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $23K sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $887K noticed on Form 144Q4 2025: $909K sold on Form 4Q1 2026: $643K noticed on Form 144Q1 2026: $663K sold on Form 4Q2 2026: $173K noticed on Form 144Q2 2026: $177K sold on Form 4Q3 2026: $163K noticed on Form 144Q3 2026: $157K sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$157K$163K
Q2 2026$177K$173K
Q1 2026$663K$643K
Q4 2025$909K$887K
Q1 2025$23K—
Q4 2024$888K$926K
Q2 2024$56K$56K
Q2 2021$2.5MNot machine-readable
Q1 2021$835KNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 21, 2025 · 4 notices
Sep 4, 20263,652 · ~$163KSep 4, 2026Sold as noticed Sold 3,652 in 2 sales, Sep 4 to Sep 4 · $157K Form 4Filing · EDGAR
Jun 4, 20263,561 · ~$173KJun 4, 2026Sold as noticed Sold 3,561 in 2 sales, Jun 4 to Jun 4 · $177K Form 4Filing · EDGAR
Mar 4, 202618,341 · ~$643KMar 4, 2026Sold as noticed Sold 18,341 in 2 sales, Mar 4 to Mar 4 · $663K Form 4Filing · EDGAR
Dec 4, 202513,278 · ~$634KDec 4, 2025Sold as noticed Sold 13,278 in 2 sales, Dec 4 to Dec 4 · $622K Form 4Filing · EDGAR
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 13, 2024 · 3 notices
Nov 5, 20257,000 · ~$253KNov 5, 2025Sold as noticed Sold 7,000 at $41.00 on Nov 5 · $287K Form 4Filing · EDGAR
Dec 3, 20247,527 · ~$332KDec 3, 2024Sold as noticed Sold 7,527 in 2 sales, Dec 3 to Feb 3 · $326K Form 4 (1) · Form 4 (2)Filing · EDGAR
Nov 12, 202415,275 · ~$594KNov 12, 2024Sold as noticed Sold 15,275 at $38.34 on Nov 12 · $586K Form 4Filing · EDGAR
Inari Medical NARI · Morgan Stanley Smith Barney · 10b5-1 plan adopted Dec 6, 2023 · 1 notice
May 20, 20241,224 · ~$56KMay 20, 2024Sold as noticed Sold 1,224 in 2 sales, May 20 to Jun 21 · $56K Form 4 (1) · Form 4 (2)Filing · EDGAR
Sales without a matching Form 144 · 6 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Notice not machine-readable Outset Medical: Sold 16,727 at $50.72 on Jun 24, 2021 · $848K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Outset Medical: Sold 16,727 at $45.11 on May 25, 2021 · $755K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Outset Medical: Sold 8,228 at $56.89 on Apr 27, 2021 · $468K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Outset Medical: Sold 8,499 at $56.33 on Apr 27, 2021 · $479K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Outset Medical: Sold 13,135 at $50.16 on Mar 25, 2021 · $659K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Outset Medical: Sold 3,592 at $49.11 on Mar 25, 2021 · $176K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Veracyte VCYT Chief Financial Officer · filings 2021 to 2026 · sold $2.8M · $2.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 4, 2026Sale under a 10b5-1 plan−2,477$42.81$106K167,200 directFiling · EDGAR
Sep 4, 2026Sale under a 10b5-1 plan−1,175$43.71$51K166,025 directFiling · EDGAR
Sep 2, 2026Shares withheld for tax or exercise price−3,603$44.88$162K169,677 directFiling · EDGAR
Jun 4, 2026Sale under a 10b5-1 plan−1,600$49.28$79K175,241 directFiling · EDGAR
Jun 4, 2026Sale under a 10b5-1 plan−1,961$50.09$98K173,280 directFiling · EDGAR
Jun 2, 2026Shares withheld for tax or exercise price−3,693$47.80$177K176,841 directFiling · EDGAR
Mar 6, 2026Grant or award from the company+36,181167,377 directFiling · EDGAR
Mar 6, 2026Grant or award from the company+13,157180,534 directFiling · EDGAR
Mar 4, 2026Sale under a 10b5-1 plan−4,400$35.55$156K145,137 directFiling · EDGAR
Mar 4, 2026Sale under a 10b5-1 plan−13,941$36.33$506K131,196 directFiling · EDGAR
Mar 2, 2026Shares withheld for tax or exercise price−7,234$36.01$260K149,537 directFiling · EDGAR
Feb 26, 2026Grant or award from the company+59,324168,820 directFiling · EDGAR
Feb 26, 2026Shares withheld for tax or exercise price−12,049$38.75$467K156,771 directFiling · EDGAR
Dec 4, 2025Sale under a 10b5-1 plan−8,537$46.61$398K114,237 directFiling · EDGAR
Dec 4, 2025Sale under a 10b5-1 plan−4,741$47.25$224K109,496 directFiling · EDGAR
Dec 2, 2025Shares withheld for tax or exercise price−3,384$46.16$156K122,774 directFiling · EDGAR
Nov 5, 2025Sale under a 10b5-1 plan−7,000$41.00$287K126,158 directFiling · EDGAR
Sep 2, 2025Shares withheld for tax or exercise price−5,371$30.11$162K133,158 directFiling · EDGAR
Jun 2, 2025Shares withheld for tax or exercise price−5,370$26.74$144K138,529 directFiling · EDGAR
Mar 6, 2025Grant or award from the company+30,200143,899 directFiling · EDGAR
Mar 2, 2025Shares withheld for tax or exercise price−11,070$34.76$385K113,699 directFiling · EDGAR
Feb 27, 2025Grant or award from the company+23,170136,680 directFiling · EDGAR
Feb 27, 2025Shares withheld for tax or exercise price−11,911$33.84$403K124,769 directFiling · EDGAR
Feb 3, 2025Sale under a 10b5-1 plan−527$43.85$23K113,510 directFiling · EDGAR
Dec 3, 2024Sale under a 10b5-1 plan−7,000$43.23$303K114,037 directFiling · EDGAR
Dec 2, 2024Shares withheld for tax or exercise price−3,464$44.12$153K121,037 directFiling · EDGAR
Nov 12, 2024Sale under a 10b5-1 plan−15,275$38.34$586K124,501 directFiling · EDGAR
Sep 2, 2024Shares withheld for tax or exercise price−3,464$31.55$109K139,776 directFiling · EDGAR
Jun 2, 2024Shares withheld for tax or exercise price−3,462$20.75$72K143,240 directFiling · EDGAR
Mar 15, 2024Grant or award from the company+4,318148,891 directFiling · EDGAR
Mar 15, 2024Shares withheld for tax or exercise price−2,189$21.10$46K146,702 directFiling · EDGAR
Mar 6, 2024Grant or award from the company+59,856144,573 directFiling · EDGAR
Mar 2, 2024Shares withheld for tax or exercise price−6,112$24.00$147K84,717 directFiling · EDGAR
Dec 2, 2023Shares withheld for tax or exercise price−1,800$26.54$48K90,829 directFiling · EDGAR
Sep 2, 2023Shares withheld for tax or exercise price−3,652$26.70$98K92,629 directFiling · EDGAR
Jun 2, 2023Shares withheld for tax or exercise price−1,183$26.72$32K95,754 directFiling · EDGAR
Mar 6, 2023Grant or award from the company+26,01496,937 directFiling · EDGAR
Mar 6, 2023Grant or award from the company
Stock Option (right to buy)
+42,95642,956 directFiling · EDGAR
Mar 2, 2023Shares withheld for tax or exercise price−2,726$24.10$66K70,923 directFiling · EDGAR
Dec 2, 2022Shares withheld for tax or exercise price−735$29.14$21K72,998 directFiling · EDGAR
Sep 2, 2022Shares withheld for tax or exercise price−3,023$19.18$58K73,733 directFiling · EDGAR
Aug 5, 2022Grant or award from the company+21,40476,756 directFiling · EDGAR
Aug 5, 2022Grant or award from the company
Common Stock
+36,49636,496 directFiling · EDGAR
Mar 3, 2022Grant or award from the company+20,72854,728 directFiling · EDGAR
Mar 3, 2022Grant or award from the company
Stock Option (right to buy)
+37,77337,773 directFiling · EDGAR
Jul 19, 2021Grant or award from the company+34,00034,000 directFiling · EDGAR
Jul 19, 2021Grant or award from the company
Stock Option (right to buy)
+67,00067,000 directFiling · EDGAR

Alamar Biosciences ALMR Director · filings 2026 to 2026

DateTransactionSharesPriceValueHeld afterSource
Apr 20, 2026Other acquisition or disposition (see the filing)
Stock Option (Right to Buy)
−140,6120 directFiling · EDGAR
Apr 20, 2026Other acquisition or disposition (see the filing)
Stock Option (Right to Buy)
+140,612140,612 directFiling · EDGAR

Inari Medical NARI Director · filings 2021 to 2025 · sold $56K · $56K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Feb 19, 2025Tendered in a change of control−9,6840 directFiling · EDGAR
Jun 21, 2024Sale under a 10b5-1 plan−260$45.99$12K9,684 directFiling · EDGAR
May 20, 2024Sale under a 10b5-1 plan−964$45.39$44K9,944 directFiling · EDGAR
Apr 24, 2024Grant or award from the company+4,126$42.41$175K10,908 directFiling · EDGAR
May 18, 2023Grant or award from the company+2,4126,782 directFiling · EDGAR
May 26, 2022Grant or award from the company+2,4204,370 directFiling · EDGAR
Jun 21, 2021Grant or award from the company+1,9501,950 directFiling · EDGAR

Outset Medical Chief Financial Officer · filings 2020 to 2021 · sold $3.4M

DateTransactionSharesPriceValueHeld afterSource
Jun 24, 2021Option or RSU exercised or converted+16,727$6.25$105K30,324 directFiling · EDGAR
Jun 24, 2021Sale under a 10b5-1 plan−16,727$50.72$848K13,597 directFiling · EDGAR
Jun 24, 2021Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−16,72777,745 directFiling · EDGAR
May 25, 2021Option or RSU exercised or converted+16,727$6.25$105K30,324 directFiling · EDGAR
May 25, 2021Sale under a 10b5-1 plan−16,727$45.11$755K13,597 directFiling · EDGAR
May 25, 2021Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−16,72794,472 directFiling · EDGAR
Apr 27, 2021Option or RSU exercised or converted+16,727$6.25$105K30,324 directFiling · EDGAR
Apr 27, 2021Sale under a 10b5-1 plan−8,499$56.33$479K21,825 directFiling · EDGAR
Apr 27, 2021Sale under a 10b5-1 plan−8,228$56.89$468K13,597 directFiling · EDGAR
Apr 27, 2021Option or RSU exercised or converted
Stock Option (Right to Buy)
−16,727111,199 directFiling · EDGAR
Mar 25, 2021Option or RSU exercised or converted+16,727$6.25$105K30,324 directFiling · EDGAR
Mar 25, 2021Sale under a 10b5-1 plan−3,592$49.11$176K26,732 directFiling · EDGAR
Mar 25, 2021Sale under a 10b5-1 plan−13,135$50.16$659K13,597 directFiling · EDGAR
Mar 25, 2021Option or RSU exercised or converted
Stock Option (Right to Buy)
−16,727127,926 directFiling · EDGAR
Mar 15, 2021Grant or award from the company
Stock Option (Right to Buy)
+27,03727,037 directFiling · EDGAR
Mar 15, 2021Grant or award from the company+13,59713,597 directFiling · EDGAR
All 56 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 4, 2026Form 144Veracyte VCYTFiling · EDGAR
Sep 4, 2026Form 4Veracyte VCYTFiling · EDGAR
Jun 4, 2026Form 144Veracyte VCYTFiling · EDGAR
Jun 4, 2026Form 4Veracyte VCYTFiling · EDGAR
Apr 20, 2026Form 4Alamar Biosciences ALMRFiling · EDGAR
Apr 16, 2026Form 3Alamar Biosciences ALMRFiling · EDGAR
Mar 10, 2026Form 4Veracyte VCYTFiling · EDGAR
Mar 6, 2026Form 4Veracyte VCYTFiling · EDGAR
Mar 4, 2026Form 144Veracyte VCYTFiling · EDGAR
Mar 4, 2026Form 4Veracyte VCYTFiling · EDGAR
Mar 2, 2026Form 4Veracyte VCYTFiling · EDGAR
Dec 4, 2025Form 144Veracyte VCYTFiling · EDGAR
Dec 4, 2025Form 4Veracyte VCYTFiling · EDGAR
Nov 7, 2025Form 4Veracyte VCYTFiling · EDGAR
Nov 5, 2025Form 144Veracyte VCYTFiling · EDGAR
Sep 4, 2025Form 4Veracyte VCYTFiling · EDGAR
Jun 4, 2025Form 4Veracyte VCYTFiling · EDGAR
Mar 10, 2025Form 4Veracyte VCYTFiling · EDGAR
Mar 3, 2025Form 4Veracyte VCYTFiling · EDGAR
Feb 19, 2025Form 4Inari Medical NARIFiling · EDGAR
Feb 5, 2025Form 4Veracyte VCYTFiling · EDGAR
Dec 4, 2024Form 4Veracyte VCYTFiling · EDGAR
Dec 3, 2024Form 144Veracyte VCYTFiling · EDGAR
Nov 14, 2024Form 4Veracyte VCYTFiling · EDGAR
Nov 12, 2024Form 144Veracyte VCYTFiling · EDGAR
Sep 4, 2024Form 4Veracyte VCYTFiling · EDGAR
Jun 24, 2024Form 4Inari Medical NARIFiling · EDGAR
Jun 4, 2024Form 4Veracyte VCYTFiling · EDGAR
May 21, 2024Form 4Inari Medical NARIFiling · EDGAR
May 20, 2024Form 144Inari Medical NARIFiling · EDGAR
Apr 26, 2024Form 4Inari Medical NARIFiling · EDGAR
Mar 19, 2024Form 4Veracyte VCYTFiling · EDGAR
Mar 8, 2024Form 4Veracyte VCYTFiling · EDGAR
Mar 5, 2024Form 4Veracyte VCYTFiling · EDGAR
Dec 5, 2023Form 4Veracyte VCYTFiling · EDGAR
Sep 6, 2023Form 4Veracyte VCYTFiling · EDGAR
Jun 6, 2023Form 4Veracyte VCYTFiling · EDGAR
May 19, 2023Form 4Inari Medical NARIFiling · EDGAR
Mar 9, 2023Form 4Veracyte VCYTFiling · EDGAR
Mar 3, 2023Form 4Veracyte VCYTFiling · EDGAR
Dec 6, 2022Form 4Veracyte VCYTFiling · EDGAR
Sep 7, 2022Form 4Veracyte VCYTFiling · EDGAR
Aug 9, 2022Form 4Veracyte VCYTFiling · EDGAR
May 27, 2022Form 4Inari Medical NARIFiling · EDGAR
Mar 7, 2022Form 4Veracyte VCYTFiling · EDGAR
Jul 20, 2021Form 4Veracyte VCYTFiling · EDGAR
Jul 20, 2021Form 3Veracyte VCYTFiling · EDGAR
Jun 25, 2021Form 4Outset MedicalFiling · EDGAR
Jun 22, 2021Form 3Inari Medical NARIFiling · EDGAR
Jun 22, 2021Form 4Inari Medical NARIFiling · EDGAR
May 26, 2021Form 4Outset MedicalFiling · EDGAR
Apr 28, 2021Form 4Outset MedicalFiling · EDGAR
Mar 29, 2021Form 4Outset MedicalFiling · EDGAR
Mar 18, 2021Form 4/AOutset MedicalFiling · EDGAR
Mar 17, 2021Form 4Outset MedicalFiling · EDGAR
Sep 14, 2020Form 3Outset MedicalFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.